Primary results from the double-blind, placebo-controlled, phase III SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MCL) Meeting Abstract
| Authors: | Wang, M.; Jurczak, W.; Jerkeman, M.; Trotman, J.; Zinzani, P. L.; Walewski, J. A.; Zhu, J.; Spurgeon, S.; Goy, A.; Hamlin, P. A.; Belada, D.; Ozcan, M.; Storring, J.; Lewis, D. J.; Rivas, J. A. H.; Henninger, T.; Deshpande, S.; Qin, R.; Le Gouill, S.; Dreyling, M. H. |
| Abstract Title: | Primary results from the double-blind, placebo-controlled, phase III SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MCL) |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 17 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-10 |
| Language: | English |
| ACCESSION: | WOS:000891791500031 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.17_suppl.LBA7502 |
| Notes: | Meeting Abstract: LBA7502 -- Source: Wos |
